AI Engines For more Details: Perplexity Kagi Labs You
Cancer Treatment: Chlorambucil is classified as an alkylating agent, which means it works by interfering with the DNA of cancer cells, ultimately leading to their destruction. It is commonly used as part of combination chemotherapy regimens or as a single-agent therapy for various types of leukemia and lymphoma.
Chronic Lymphocytic Leukemia (CLL): Chlorambucil is frequently used in the treatment of CLL, a type of cancer that affects the white blood cells called lymphocytes. It can help slow the progression of the disease and improve symptoms, such as enlarged lymph nodes, fatigue, and night sweats.
Hodgkin Lymphoma: Chlorambucil may be used in the treatment of Hodgkin lymphoma, a cancer that originates in the lymphatic system. It is often combined with other chemotherapy drugs to achieve optimal outcomes in patients with this condition.
Non-Hodgkin Lymphoma: Chlorambucil is also effective in the treatment of certain types of non-Hodgkin lymphoma, which encompasses a group of lymphatic system cancers that differ from Hodgkin lymphoma. It may be used alone or in combination with other chemotherapy agents or immunotherapy drugs.
Side Effects: Common side effects of chlorambucil chemotherapy may include nausea, vomiting, diarrhea, decreased appetite, hair loss, fatigue, and increased susceptibility to infections due to suppression of the immune system. Some individuals may also experience bone marrow suppression, leading to low blood cell counts (anemia, leukopenia, and thrombocytopenia), which can increase the risk of bleeding and infections.
Long-term Side Effects: Chlorambucil treatment may have long-term effects on various organ systems, including the kidneys, liver, and reproductive system. Regular monitoring of organ function and blood cell counts is essential during and after treatment with chlorambucil.
Secondary Cancers: Like many chemotherapy drugs, chlorambucil may increase the risk of developing secondary cancers, particularly leukemia or lymphoma, years after the completion of treatment. This risk should be weighed against the potential benefits of treatment.
Contraindications: Chlorambucil is contraindicated in individuals with known hypersensitivity to the drug and those with severe bone marrow suppression or active infections. It should be used with caution in individuals with pre-existing kidney or liver disease.
Rank | Probiotic | Impact |
---|---|---|
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
Taxonomy | Rank | Effect | Citations | Notation |
---|---|---|---|---|
Coprococcus | genus | Decreases | 👪 Source Study | |
Parabacteroides | genus | Decreases | 👪 Source Study | BMI, fat percent,blood pressure |
Thomasclavelia | genus | Decreases | 👪 Source Study | |
Streptococcus | genus | Decreases | 👪 Source Study | |
Coprococcus comes | species | Decreases | 📓 Source Study | |
Parabacteroides distasonis | species | Decreases | 📓 Source Study | |
Thomasclavelia ramosa | species | Decreases | 📓 Source Study | |
Streptococcus parasanguinis | species | Decreases | 📓 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.1 | 0.2 | -1 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | -0.1 | |
Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
Allergy to milk products | 0.1 | -0.1 | |
Alopecia (Hair Loss) | 0.1 | 0.1 | |
Alzheimer's disease | 0.1 | 0.2 | -1 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.2 | |
Ankylosing spondylitis | 0.2 | 0.2 | |
Anorexia Nervosa | 0.1 | 0.1 | |
Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
Atrial fibrillation | 0.4 | 0.1 | 3 |
Autism | 0.4 | 0.4 | 0 |
Barrett esophagus cancer | 0.1 | -0.1 | |
Biofilm | 0.1 | 0.1 | |
Bipolar Disorder | 0.1 | 0.2 | -1 |
Carcinoma | 0.1 | 0.1 | 0 |
Celiac Disease | 0.1 | 0.1 | 0 |
Cerebral Palsy | 0.1 | 0.1 | |
Chronic Fatigue Syndrome | 0.1 | 0.9 | -8 |
Chronic Kidney Disease | 0.1 | 0.2 | -1 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.2 | 0 |
Chronic Urticaria (Hives) | 0.1 | 0.1 | |
Coagulation / Micro clot triggering bacteria | 0.1 | 0.1 | 0 |
Colorectal Cancer | 0.1 | 0.1 | |
Coronary artery disease | 0.2 | -0.2 | |
COVID-19 | 0.2 | 0.4 | -1 |
Crohn's Disease | 0.3 | 0.3 | 0 |
deep vein thrombosis | 0.1 | -0.1 | |
Depression | 0.4 | 0.8 | -1 |
Dermatomyositis | 0.1 | 0.1 | |
Eczema | 0.1 | -0.1 | |
Endometriosis | 0.4 | 0.4 | |
Epilepsy | 0.1 | 0.1 | 0 |
Fibromyalgia | 0.2 | 0.5 | -1.5 |
Functional constipation / chronic idiopathic constipation | 0.1 | 0.2 | -1 |
gallstone disease (gsd) | 0.1 | 0.1 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | -0.1 | |
Generalized anxiety disorder | 0.2 | -0.2 | |
Glioblastoma | 0.1 | -0.1 | |
Gout | 0.2 | -0.2 | |
Graves' disease | 0.1 | 0.1 | |
Halitosis | 0.1 | -0.1 | |
Hidradenitis Suppurativa | 0.1 | 0.1 | |
hyperglycemia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 0.1 | 0.3 | -2 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0.1 | 0.1 | |
Inflammatory Bowel Disease | 0.2 | 0.4 | -1 |
Insomnia | 0.1 | 0.1 | |
Intelligence | 0.2 | 0.2 | |
Intracranial aneurysms | 0.1 | 0.1 | |
Irritable Bowel Syndrome | 0.1 | -0.1 | |
Liver Cirrhosis | 0.4 | 0.3 | 0.33 |
Long COVID | 0.7 | 0.3 | 1.33 |
Low bone mineral density | 0.2 | -0.2 | |
Mast Cell Issues / mastitis | 0.1 | 0.2 | -1 |
ME/CFS with IBS | 0.1 | 0.5 | -4 |
ME/CFS without IBS | 0.1 | 0.1 | 0 |
Metabolic Syndrome | 0.4 | 0.4 | 0 |
Mood Disorders | 0.6 | 0.8 | -0.33 |
multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
Multiple Sclerosis | 0.2 | 0.3 | -0.5 |
Multiple system atrophy (MSA) | 0.1 | 0.1 | |
Neuropathy (all types) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.2 | -1 |
Obesity | 0.4 | 0.3 | 0.33 |
obsessive-compulsive disorder | 0.1 | 0.2 | -1 |
Osteoarthritis | 0.2 | 0.2 | |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 0.4 | 0.4 | 0 |
Polycystic ovary syndrome | 0.1 | 0.1 | |
Postural orthostatic tachycardia syndrome | 0.2 | -0.2 | |
Premenstrual dysphoric disorder | 0.1 | -0.1 | |
Psoriasis | 0.1 | 0.4 | -3 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.4 | 0.2 | 1 |
Schizophrenia | 0.3 | 0.2 | 0.5 |
scoliosis | 0.2 | 0.2 | |
Sjögren syndrome | 0.1 | 0.1 | 0 |
Sleep Apnea | 0.2 | 0.2 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
Stress / posttraumatic stress disorder | 0.1 | 0.2 | -1 |
Systemic Lupus Erythematosus | 0.4 | 0.4 | |
Type 1 Diabetes | 0.2 | 0.1 | 1 |
Type 2 Diabetes | 0.4 | 0.4 | 0 |
Ulcerative colitis | 0.1 | 0.3 | -2 |
Unhealthy Ageing | 0.3 | 0.2 | 0.5 |
Vitiligo | 0.1 | 0.5 | -4 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [34.204.176 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.204.176 ]